Neurocrine Biosciences | NBIX - 营业利润



金融业
股票价格
USD
资产
USD 4.91B
现金及等价物
USD 266.5M
销售成本
USD 13.8M
流动资产
USD 2.44B
流动负债
USD 831.7M
债务
USD 406.2M
EBIT
USD 214.6M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 1.94
股本和储备
USD 3.41B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 16.69B
净收入
USD 197.9M
营业费用
USD 599.9M
营业利润
USD 214.6M
普通股股本
USD 100.6M
PE价格收益
28.09
税前利润
USD 246.8M
销售收入
USD 811M
销售和管理费用
USD 318.5M
股票
USD 64.5M
贸易债权人
USD 691.3M
应收帐款人
USD 768.1M


营业利润 更改 日
AbbVie USD 4.73B 1.08B 2026-03
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
ALKERMES USD -48.28M 37.33M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amgen USD 3.83B 130M 2026-03
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Cytokinetics USD -181.23M 2.86M 2026-03
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Exelixis USD 251.34M 15.43M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Incyte USD 324.17M 59.7M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Pfizer USD 4.99B 340M 2026-03
Prothena USD 25.79M 53M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Repligen USD 19.98M 13K 2026-03
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Teva Pharmaceutical Industries USD 758M 271M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03
Xoma USD -15.64M 5.56M 2024-09